Richman Chemical Launches Funding Opportunity Reports for Start-Ups Seeking Funding or Licensing Opportunities in the Life Science and Specialty Chemical Markets

Philadelphia, PA, May 12, 2015 -- Richman Chemical Inc. (RCI) today announced the commercial launch of Funding Opportunity Reports (FORs) to assist technology start-ups and emerging life science and specialty chemical businesses in securing funding for product development and manufacturing.

The FOR identifies and recommends funding options based on the different requirements of investors and funding organizations. Funding sources include venture capital (VC) groups, angel investor consortiums and grant opportunities available through governmental agencies such as NIH. The report also identifies and recommends licensing opportunities with commercial partners including large pharmaceutical companies with synergistic or complementary technologies.

“Securing adequate capital for product development and manufacturing is a highly competitive process, yet it is vital for start-up companies to develop relationships with funding organizations interested in supporting such novel technologies,” commented Christopher Kulp, Executive Vice President at Richman Chemical. He continued, “We have long-standing relationships with a variety of resources that provide grants or investment capital, as well as those looking for licensing opportunities.”

Furthermore, for companies interested in pursuing licensing opportunities, RCI provides proof-of-concept work, data collection and analysis (including synthesis, testing and formulation work) as required by investors considering funding. This is often one of the most expensive and difficult steps in the life of a start-up. While fledgling companies usually can confirm the bioactivity of a drug candidate on their own, their ability to prepare a comprehensive technical package suitable for licensing or transfer often remains beyond their internal capabilities.   

The FOR is an excellent complement to RCI’s Technology Assessment Report (TAR).  University technology transfer offices and emerging technology organizations benefit from the TAR with advice on the feasibility of their technology based on "as-is" production processes and receive cost-effective production improvement strategies and recommendations for accelerated commercialization.

About Richman Chemical

Richman Chemical, Inc. provides custom chemical synthesis, custom manufacturing and raw material sourcing in the life sciences, specialty chemical, biotechnology, pharmaceutical and emerging technology industries.  RCI’s Consulting Services include patent research, analysis and recommendation of process changes, identification of qualified investment resources, technology licensing guidance and more. Founded in 1988 by Ed Richman, the company is headquartered outside of Philadelphia.  For more information visit www.richmanchemical.com  and follow us on LinkedIn.

 

 

Media Contact:
Gail McGrew

McGrew Marketing

215-262-5284

gail@mcgrewmarketing.com